FRANKFURT, Nov 14 (Reuters) - Merck KGaA (MRCG.DE), opens new tab on Thursday reported a gain of 11.9% in adjusted quarterly ...

The life-sciences and chemical group said it now expects 2024 net sales in the lower half of its previously expected range of ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions.

AIDDISON also encompasses SA-space, a synthetically accessible chemical space of approximately 25 billion virtual compounds built on the Sigma-Aldrich catalogue of molecules that are readily ...

As a wave of patent expirations encroaches upon many of the world’s top drugmakers, companies will need to be diligent in ...

Merck’s Animal health and vaccine products are core growth drivers. It has a strong cancer pipeline, including Keytruda.

Merck's Q3 revenue rises, led by Keytruda's strong 17% YoY growth. Gardasil demand challenges in China impact sales, with ...

Anyone crafting a bull case for the pharmaceutical giant Merck (NYSE: MRK) should include Keytruda as the company's best asset. The cancer drug has been Merck's top-selling medicine and its ...

Oct 17 (Reuters) - (This Oct. 17 story has been corrected to say that the drug reduced some types of respiratory infection, not all, in the headline and paragraphs 1 and 2) Merck (MRK.N), opens ...

The company saw strong sales from its top-selling cancer drug Keytruda, recently launched treatments and its animal health ...

and the percentage of total revenues each product accounts for. We might conclude that Merck actually delivered a fairly impressive performance in Q2, with key divisions such as Oncology ...

Germany’s Merck KGaA expects annual sales to be at the lower half of its outlook range after third-quarter sales missed ...